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Left ventricular noncompaction (LVNC) is a heterogeneous
myocardial disorder characterized by prominent left ventric-
ular trabeculae and deep intertrabecular recesses with vari-
able clinical features. The classical triad of complications is
heart failure, thromboembolic events, and arrhythmias
including sudden cardiac death. LVNC has been recognized
as a primary cardiomyopathy of genetic origin.1 However,
the genetic basis of the disease in a large proportion of
patients with LVNC remains unresolved. The ﬁrst genetic
cause of isolated LVNC was described in the X-linked
tafazzin gene,2 the gene also responsible for Barth syndrome,
in patients and carrier females. Recently, multiple causal
genes have been identiﬁed.3
Sarcomere gene mutations are generally considered to be
causative for hypertrophic cardiomyopathy and dilated
cardiomyopathy.3 In 2007, Monserrat et al. ﬁrst reported a
sarcomeric mutation in Spanish LVNC families and identi-
ﬁed ACTC1 (which encodes α-cardiac actin) as the causal
gene.4
Here we describe clinical and molecular investigations in
a rare case of young boy with LVNC and novel mutation of
the ACTC1 (c.692C4G, p.T231R).Case report
A 4-year-old boy was referred to our cardiac intensive care
unit because of ventricular tachyarrhythmias causing hypo-
tensive shock. The patient was of mixed heritage (halfKEYWORDS ACTC1; Child; Left ventricular noncompaction; Sarcomere
protein genes; Ventricular arrhythmias
ABBREVIATIONS ACTC1 ¼ actin, a-cardiac muscle 1 gene; ECG ¼
electrocardiogram; LVNC ¼ left ventricular noncompaction
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of cardiac disease; he had experienced recurrent syncope
beginning at age 3 years. Results of basic evaluations
after each syncopal event were normal. He was initially
diagnosed with epilepsy. Eight months after the onset of
syncope, he experienced cardiopulmonary arrest after mild
exercise. He was resuscitated and transferred to a local
hospital for hypothermic therapy. On admission, the electro-
cardiogram (ECG) showed mild sinus bradycardia. The
following day, the patient experienced the sudden onset of
ventricular tachycardia that degenerated into ﬁbrillation,
without evidence of ischemia or electrolyte abnormalities.
After resuscitation and electrical deﬁbrillation, sinus rhythm
was restored. The patient was started on a continuous
amiodarone infusion and transported to our hospital for
further evaluation and treatment.
On arrival, the patient was still bradycardic. Blood tests
showed an elevated brain natriuretic peptide concentration of
550 pg/mL. A 12-lead ECG showed biventricular hyper-
trophy with normal QT/QTc intervals. A 2-dimensional
echocardiogram revealed prominent trabeculations and deep
intertrabecular recesses at the apical, anterolateral, and
posterior regions of the left ventricle (Figure 1A). The left
ventricular ejection fraction was mildly decreased at 49%.
A tiny trabecular muscular ventricular septal defect was also
observed.
After the patient was extubated and regained conscious-
ness, he underwent cardiac catheterization. The cardiac index
was found to be slightly decreased, to 2.8 L/min/m2. A
coronary angiogram was normal. The programmed stimula-
tion did not induce any arrhythmia with or without iso-
proterenol infusion. His signal-averaged ECG did not reveal
delayed potentials.
After other types of secondary cardiomyopathies (infec-
tive, inﬁltrative, storage, autoimmune, and neuromuscular)
were ruled out, the patient was diagnosed with LVNC. Barth
syndrome was ruled out, owing to the lack of other
characteristics such as neutropenia, hypotonia, muscle weak-
ness, or undeveloped skeletal muscles.pen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.11.008
KEY TEACHING POINTS
 Left ventricular noncompaction (LVNC) has been
recognized as a genetic primary cardiomyopathy;
its causative genes are heterogeneous and include
sarcomeric protein genes.
 Compared with adult patients with LVNC, pediatric
patients with LVNC experience ventricular
arrhythmias relatively rarely.
 A novel ACTC1 mutation (c.692C4G, p.T231R) was
detected in a young boy with LVNC, repeated
syncope, and resuscitated ventricular arrhythmias;
this mutation could be related to potentially fatal
arrhythmias in LVNC patients.
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tachycardia at 170 beats per minute were observed on
ECG monitoring (Figure 1B); the patient was treated with
intravenous landiolol (an ultrashort-acting β1-blocker) in
addition to the oral amiodarone. A secondary prevention
epicardial implantable cardioverter deﬁbrillator was placed
(Figure 1C). The patient received standard heart-failure
therapies (diuretics, angiotensin 1-converting enzyme inhib-
itor, and oral β-blocker) and anticoagulant therapy and was
discharged on hospital day 51 without neurologic sequelae.
He did not have any cardiac events with the prophylactic
administration of oral amiodarone and β-blocker during 2
years’ follow-up.Molecular studies
After obtaining informed consent from the parents of the
patient, DNA was isolated from a peripheral blood sample of
the patient and was screened for mutations by direct
sequencing. A novel heterozygous missense variant in
ACTC1 (c.692C4G, p.T231R) was identiﬁed (Figure 2A),
and it was considered to be possibly pathogenic on in silico
analysis. His parents refused genetic testing of themselves
because they were healthy and asymptomatic.
The ACTC1 variant was considered to be a likely
pathogenic mutation based on the following criteria: (1) it
was de novo and present in blood; (2) it was not detected in
400 unrelated chromosomes of ethnicity-/race-matched con-
trol subjects; (3) it was not reported in public databases such
as the National Center for Biotechnology Information’s
dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/) or the
National Heart, Lung, and Blood Institute’s Grand Oppor-
tunity Exome Sequencing Project Exome Variant Server
(http://evs.gs.washington.edu/EVS/); (4) it affected evolutio-
narily conserved residues (nucleotide and amino acid:
Figure 2B); and (5) it was predicted to be deleterious/
pathogenic by multiple in silico algorithms (Polyphen2,
PANTHER, Align GVGD, SIFT, and Mutation Taster).
No mutation was identiﬁed in the TAZ, LMNA/C, LDB3,
DTNA, MIB1, PRDM16, YWHAE, MYBPC3, TNNT2, TNNI3,ACTC, or TPM1 gene. In addition, no mutation was
identiﬁed in RYR2 or CASQ2, where several mutations have
been identiﬁed in patients with catecholaminergic polymor-
phic ventricular tachycardia.Discussion
We present a rare case of LVNC associated with a likely
pathogenic novel mutation of the ACTC1 gene (c.692C4G,
p.T231R). A young boy was diagnosed with LVNC after
cardiopulmonary arrest that was probably caused by a
potentially fatal ventricular arrhythmia. The ventricular
arrhythmia and recurrent syncope associated with LVNC
are highlighted in the present case.
More than 100 mutations within the α-skeletal muscle
actin gene (ACTA1) are known and are responsible for 20%
of congenital myopathies, whereas only 12 mutations within
ACTC1 have been identiﬁed and are correlated with diseases
such as cardiomyopathies and atrial septal defects5–11
(Figure 2C). A phenotypic variation was reported in LVNC
families with sarcomeric mutations.4
As a cytoskeletal protein, actin is ubiquitously expressed
in eukaryotic cells and is involved in an extraordinary array of
cellular functions. Besides its classic role in muscle contrac-
tion, actin also plays important roles in cellular processes
such as gene transcription, chromosome morphology,
cell cycle control, modulation of a variety of membrane
responses, translation of several messenger RNA species,
modulation of enzyme activity and intracellular localization,
and cellular apoptosis.12,13 Several studies have shown that
these roles could be affected by mutations in genes that affect
actin.14 In the present case, a T231R mutation may lie within
the TPM1-binding domain because of an A232V mutation
located in the TPM1-binding domain identiﬁed in hyper-
trophic patients, and it may result in mutation-speciﬁc
disturbances in the actin–actin and actomyosin interactions,
which could subsequently lead to LVNC.
In LVNC patients with reduced systolic left ventricular
function, the major clinical manifestations include heart
failure symptoms, arrhythmias, and embolic events. Various
patterns of arrhythmia can be observed in LVNC patients.
Previously, 2 ACTC1 mutations have been described in
LVNC patients; their clinical presentation varies from
asymptomatic to disabling heart failure (Table 1).4,5,15 Spe-
ciﬁcally, the course of the disease caused by the major
mutation c.478G4A, p.E101K is typically benign, and
sudden death is an exception occurring in patients with more
severe wall thickening and/or systolic dysfunction.4,5 On the
other hand, Tian et al.15 reported a case of middle-aged
woman with LVNC and ACTC1 mutation (c.986T4C,
p.I329T), who had syncope and palpitation, ventricular
ﬁbrillation, atrial ﬁbrillation, and a left bundle branch block.
Her son was also diagnosed with LVNC and died suddenly at
age 12 years. In the present case, the young boy with LVNC
had a novel ACTC1 mutation, and his arrhythmic phenotype
was severe with mild left ventricular dysfunction. Although
current evidence appears to suggest that sarcomeric mutations
Figure 1 A: A 2-dimensional echocardiogram recorded on admission. Bidirectional arrows indicate a noncompaction layer, and solid lines indicate a
compaction layer in the left ventricle. Note the prominent trabeculations and deep intertrabecular recesses in the left ventricle. B: Lead II monitor
electrocardiogram recorded on hospital day 14 showing sustained ventricular tachycardia with a heart rate of 150–170 bpm. C: The images shows the epicardial
bipolar electrodes placed on the right atrium and ventricle, the shock coil placed on posterior of the left atrium through transverse sinus, and the implantable
cardioverter deﬁbrillator placed in the intraperitoneal space.
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Figure 2 A: Sequence analysis of exon 5 in ACTC1 of the proband showing results for the DNA sample isolated from a blood sample. The electropherograms
show the heterozygous C4G substitution resulting in the threonine-to-arginine missense mutation. The putative amino acid sequence is shown above the
nucleotide sequence. B: Alignment of the regions ﬂanking the novel mutation in ACTC1 showing evolutionary conservation of the mutated residue across
species (boxed). Dots indicate amino acids identical to the one in the human sequence. C: Structure of the ACTC1 indicating the position of the mutations
previously described (black) and our novel variant (red), which are all highly conserved across species. ASD = atrial septal defect; DCM = dilated
cardiomyopathy; HCM = hypertrophic cardiomyopathy; LVNC ¼ left ventricular noncompaction; RCM = restrictive cardiomyopathy.
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Table 1 Clinical characteristics of patients with left ventricular noncompaction and ACTC1 mutations
Age(y)/
sex Exon
Coding DNA
change
Protein
change
Mutation
type NYHA
LVEF/FS
% ECG ﬁndings
Cardiovascular
complications Reference
15/F 3 c.478G4A p.E101K missense I 60/32 syncope,PM 4
58/M 3 c.478G4A p.E101K missense III 30/22 syncope,CHF,PH 4
38F 3 c.478G4A p.E101K missense III 68/33 AF,ST depression CHF,PH 4
73/M 3 c.478G4A p.E101K missense II 40/17 4
56/M 3 c.478G4A p.E101K missense I 53/31 LVH 3
54/F 3 c.478G4A p.E101K missense I 50/29 3
52/M 3 c.478G4A p.E101K missense I 61/37 3
31/F 3 c.478G4A p.E101K missense I 69/43 3
26/F 3 c.478G4A p.E101K missense I 68/43 3
20/F 3 c.478G4A p.E101K missense I 66/41 3
15/F 3 c.478G4A p.E101K missense I 71/45 3
16/M 3 c.478G4A p.E101K missense I 67/42 LVH ASD 3
15/M 3 c.478G4A p.E101K missense I 70/45 LVH,abnQ syncope 3
13/F 3 c.478G4A p.E101K missense I 71/45 LVH MR 3
10/M 3 c.478G4A p.E101K missense I 65/40 LVH,abnQ 3
7/M 3 c.478G4A p.E101K missense I 83/57 LVH 3
5/F 3 c.478G4A p.E101K missense I 66/41 LVH,abnQ 3
26/M 3 c.478G4A p.E101K missense I 54/32 LVH,abnQ 3
10/M 3 c.478G4A p.E101K missense I 59/35 LVH VSD 3
62/M 3 c.478G4A p.E101K missense I 66/42 ASD 3
81/M 3 c.478G4A p.E101K missense III 54/32 LVH 3
35/M 3 c.478G4A p.E101K missense I 60/36 LVH 3
29/F 3 c.478G4A p.E101K missense I 61/37 3
28/F 3 c.478G4A p.E101K missense II 56/33 LVH,abnQ 3
5/M 3 c.478G4A p.E101K missense I 3
55/F 3 c.478G4A p.E101K missense II 65/40 3
15/F 3 c.478G4A p.E101K missense I 53/31 LVH,abnQ 3
4/M 5 c.692C4G p.T231R missense I 49/ LVH,VF,VT,
bradycardia
VSD this study
48/F 6 c.986T4C p.I329T missense I 48/27 VF,AF,LBBB 15
abnQ ¼ abnormal Q wave; AF ¼ atrial ﬁbrillation; ASD ¼ atrial septal defect; CHF ¼ chronic heart failure; CPA ¼ cavopulmonary arrest; FS ¼ fraction
shortening; LBBB¼ left branch bundle block; LVEF¼ left ventricular ejection fraction; LVH¼ left ventricular hypertrophy; NYHA¼ New York Heart Association;
PH ¼ pulmonary hypertension; PM ¼ pacemaker; VF ¼ ventricular ﬁbrillation; VSD ¼ ventricular septal defect; VT ¼ ventricular tachycardia.
Heart Rhythm Case Reports, Vol 2, No 1, January 201696do not predict a clinical phenotype in LVNC, the phenotype–
genotype relationship may exist among LVNC patients with
ACTC1 mutations.
In conclusion, these observations suggest that some
LVNC patients with mutations in the ACTC1 gene could
have potentially fatal arrhythmias and should be evaluated to
determine their risk of sudden cardiac death.
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